文献速递外周动脉疾病

2001-2021年北美外周动脉疾病随机对照试验女性入组率的Meta分析

A Meta-Analysis of Female Enrollment in Peripheral Artery Disease Randomized Controlled Trials in North America: 2001-2021.
PubMed 文献 · Ann Vasc Surg · 2026-09-05

该系统评价检索2001年至2021年6月在美国或加拿大开展的外周动脉疾病随机对照试验,纳入103项RCT共75776名参与者。随机效应合并的女性参与者比例为0.30(95%CI 0.21-0.40),异质性显著,非NIH/联邦/州政府资助的试验女性入组率更低(8% vs NIH 35%,行业资助0.30;P<0.01)。结论认为女性在外周动脉疾病试验中入组比例偏低,证据外推至女性存在局限。

要点

  • 2001-2021年北美PAD随机对照试验中女性合并比例为0.30(95%CI 0.21-0.40)。
  • 非NIH/联邦/州政府资助试验女性入组率8%,低于NIH资助的35%(P<0.01)。
  • 女性入组不足使PAD干预证据对女性的普遍性受限。

核心结论

  • 该系统分析显示,无论试验目的、资助来源或地理区域,女性在PAD临床试验中的入组比例均偏低。
  • 当前PAD干预的循证治疗证据主要从男性观察数据外推,对女性的普遍性可能有限。

研究设计与样本

  • 系统文献检索多个数据库,纳入2001年至2021年6月在美国或加拿大开展的PAD随机对照试验。
  • 共纳入103项RCT,总参与者75776名,其中女性48120名。
  • 采用随机效应Meta分析(逆方差合并)估计女性百分比的合并值。

主要发现

  • 98项(95.1%)试验报告了参与者性别。
  • 40项(40.8%)试验发表于2001-2010年,58项(59.2%)发表于第二个十年。
  • 随机效应合并的女性参与者比例为0.30(95%CI 0.21-0.40),异质性显著。
  • 不同试验类型间总体女性比例无显著差异。
  • 非NIH、联邦或州政府机构资助的试验女性入组率更低(8% vs NIH 35%,行业资助0.30;P<0.01)。

关键数值与推荐

  • 女性合并比例为0.30(95%CI 0.21-0.40)。
  • 非NIH/联邦/州政府资助试验女性入组率8%,NIH资助为35%,行业资助为0.30(P<0.01)。

临床怎么用

  • 解读PAD干预证据时应考虑女性入组不足对结果外推性的限制。
  • 设计或评估PAD临床试验时需关注女性招募的代表性及资助来源对入组的影响。

局限性

  • 合并比例异质性显著。
  • 仅纳入美国或加拿大开展的试验,地理范围有限。
  • 部分试验未报告性别数据(103项中98项报告)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the recent improvement in female recruitment to randomized controlled medical research trials (RCTs), males continue to predominate in cardiovascular trials due to multiple structural barriers. Scarce data are available on female representation in peripheral artery disease (PAD) trials. This study aimed to analyze the reporting of gender and quantify female enrollment rates in PAD RCTs, the impact of trial funding sources, and geographic factors over 2 decades. METHODS: A systematic literature search across multiple databases was performed to retrieve PAD RCTs conducted in the United States or Canada from 2001 to June 2021. Extracted data included the trial year, country, geographic region, number of recruitment sites, sample size, sex reporting/composition, follow-up duration, and funding source. A pooled estimate of the female percentages across studies was performed using the random effects meta-analysis with inverse variance pooling. RESULTS: A total of 103 RCTs were included. 98 (95.1%) trials reported their participants' sex. In total, 40 (40.8%) trials were published in 2001-2010, while the rest, 58 (59.2%), were published over the second decade. A total of 75,776 participants were enrolled, 48,120 females, corresponding to an aggregate female enrollment proportion of 63.5%. The random-effects pooled proportion of female participants was 0.30 (95% confidence interval, 0.21-0.40), with substantial heterogeneity. There were no significant differences in overall female proportions across different trial types. Studies that were sponsored by non-National Institutes of Health (NIH), federal, or state governmental agencies demonstrated disproportionately lower rates of female enrollment (8% vs. 35% in NIH, 0.30 industry-sponsored RCTs; P < 0.01). CONCLUSION: The enrollment of women was disproportionately low in this systematic analysis of PAD clinical trials, regardless of trial purpose, funding source, or geographic site, when compared to men. The analyzed trials occurred for 2 decades following nonenforceable federal mandates to improve female and minority trial enrollment. As a result, the current purported evidence-based treatment of PAD interventions in women is based on data disproportionately extrapolated from observations of PAD in men. These findings suggest that the evidence base supporting PAD interventions may have limited generalizability to women as they remain underrepresented among PAD trial participants. A coordinated effort on behalf of investigators, professional societies, industry, and government sponsors is necessary to overcome this research enrollment finding, which calls into question the fidelity of contemporary PAD treatment strategies.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kirksey L, Khan A, Bertolino EP, et al. A Meta-Analysis of Female Enrollment in Peripheral Artery Disease Randomized Controlled Trials in North America: 2001-2021. Ann Vasc Surg. 2026. PMID: 42697326. doi:10.1016/j.avsg.2026.08.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。